CHRS Q2 2023 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M-2.4% YoY

Gross Profit

$34M57.7% margin

Operating Income

-$35M-58.8% margin

Net Income

-$43M-73.0% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+81.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$470M

Total Liabilities

$644M

Stockholders' Equity

-$175M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$60M	-2.4%
Gross Profit	$34M	$49M	-30.7%
Operating Income	-$35M	-$44M	+21.5%
Net Income	-$43M	-$50M	+14.5%

Revenue Segments

Product Revenue

$58M100%

Other

$259,0000%